EPH148 Insights From a French Postmarketing Authorization Early Access (MA EA) Mechanism: Projecting Clinical and Economic Benefits of Neoadjuvant Nivolumab–Platinum-Based Chemotherapy (PDC) in Resectable Non-Small Cell Lung Cancer
Abstract
Authors
Paul Casabianca Jérémy CARETTE Stefano Lucherini Melanie Chartier Henri Leleu Christos CHOUAID FRANCOIS-EMERY COTTE